BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust
07-Feb-2006
BTG and the technology transfer division of the Wellcome Trust also announced that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.